Saturday, September 02, 2006

Personalized Medicine's High Cost of Entry

A recent Chicago Tribune article canvasses the difficulties that academics and drug manufacturers alike are encountering in their attempts to make personalized medicine, or pharmacogenomics, profitable enough to pursue.

An interesting side note: the Tribune article touts Herceptin, an anti-breast cancer drug, as one of the few success stories of personalized medicine to date. Unfortunately, a recent study has found that Herceptin carries a greater heart damage risk than previously thought.

While this news doesn't repudiate Herceptin's therapeutic value it does serve as a careful reminder: even personalized medicine is not perfect medicine.


Post a Comment

Links to this post:

Create a Link

<< Home